Publications 2016-2024
Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient-derived in vitro model. van Nieuwenhuijzen N, Cuenca M, Abbink L, Jak M, Peperzak V, Minnema MC. EJHaem. 2023 Nov 29;5(1):141-146. PMID: 38406516​
​
Bridging the gap between scientific discoveries and clinical application at the Utrecht Science Park. Peperzak V, Coquet JM. Immunol Cell Biol. 2024 Apr;102(4):232-234. PMID: 38058197
​
Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients. Beltrán-Visiedo M, Jiménez-Alduán N, Díez R, Cuenca M, Benedi A, Serrano-Del Valle A, Azaceta G, Palomera L, Peperzak V, Anel A, Naval J, Marzo I. Mol Oncol. 2023 Dec;17(12):2507-2525. PMID: 37704591
​
Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma. Greve P, Beishuizen A, Hagleitner M, Loeffen J, Veening M, Boes M, Peperzak V, Diez C, Meyer-Wentrup F. Front Immunol. 2023 Jul 31;14:1229558. PMID: 37583696
​
Serpin B9 controls tumor cell killing by CAR T cells. Kimman T, Slomp A, Martens A, Grabherr S, Li S, van Diest E, Meeldijk J, Kuball J, Minnema MC, Eldering E, Bovenschen N, Sebestyén Z, Peperzak V. J Immunother Cancer. 2023 Mar;11(3):e006364. PMID: 36931661
​
Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma. Spaan I, van Nieuwenhuijzen N, Kimman T, Rockx-Brouwer D, Tieland RG, Maurice MM, Minnema MC, Raymakers RA, Peperzak V. Blood Adv. 2023 Apr 11(7):1103-1107. PMID: 36459495
​​
Inhibitory pattern recognition receptors. Rumpret M, von Richthofen HJ, Peperzak V, Meyaard L. J Exp Med. 2022 Jan 3;219(1):e20211463. PMID: 34905019
​
Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition. Cuenca M, Van Nieuwenhuijzen N, Moesbergen LM, Bloem A, Minnema MC, Peperzak V. Haematologica. 2022 Apr 1;107(4):980-983. PMID: 34879645
​
Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1. Spaan I, van de Stolpe A, Raymakers RA, Peperzak V. Cancers (Basel). 2021 Sep 17;13(18):4668. PMID: 34572895
​
Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma. Spaan I, Timmerman LM, Kimman T, Slomp A, Cuenca M, van Nieuwenhuijzen N, Moesbergen LM, Minnema MC, Raymakers RA, Peperzak V. Blood Adv. 2021 Jun 22;5(12):2593-2607. PMID: 34152396
Advances and Perspectives in the Treatment of B-Cell Malignancies. Cuenca M, Peperzak V. Cancers (Basel). 2021 May 8;13(9):2266. PMID: 34066840
​
Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells. Slomp A, Moesbergen LM, Eldering E, Kersten MJ, Minnema MC, Peperzak V. Cell Death Dis. 2021 Mar 3;12(3):229. PMID: 33658484
​
​Upcoming immunotherapeutic combinations for B-cell lymphoma. Greve P, Meyer-Wentrup FAG, Peperzak V, Boes M. Immunother Adv. 2021 Feb 9;1(1):ltab001. PMID: 35919738
​
Endochondral Bone Regeneration by Non-autologous Mesenchymal Stem Cells. Longoni A, Pennings I, Cuenca Lopera M, van Rijen MHP, Peperzak V, Rosenberg AJWP, Levato R, Gawlitta D. Front Bioeng Biotechnol. 2020 Jul 9;8:651. PMID: 32733861
​
Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Slomp A, Moesbergen LM, Gong JN, Cuenca M, von dem Borne PA, Sonneveld P, Huang DCS, Minnema MC*, Peperzak V*. Blood Adv. 2019 Dec 23;3(24):4202-4214. PMID: 31856269
​
Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma. Slomp A, Peperzak V. Front Oncol. 2018 Nov 20;8:533. PMID: 30524962
​
Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. Spaan I, Raymakers RA, van de Stolpe A, Peperzak V. J Hematol Oncol. 2018 May 18;11(1):67. PMID: 29776381
​
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells. van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. Cancer Res. 2018 May 15;78(10):2449-2456. PMID: 29703720
​
DNA-binding of the Tet-transactivator curtails antigen-induced lymphocyte activation in mice. Ottina E, Peperzak V, Schoeler K, Carrington E, Sgonc R, Pellegrini M, Preston S, Herold MJ, Strasser A, Villunger A. Nat Commun. 2017 Oct 18;8(1):1028. PMID: 29044097
​
c-Myb Regulates the T-Bet-Dependent Differentiation Program in B Cells to Coordinate Antibody Responses. Piovesan D, Tempany J, Di Pietro A, Baas I, Yiannis C, O'Donnell K, Chen Y, Peperzak V, Belz GT, Mackay CR, Smyth GK, Groom JR, Tarlinton DM, Good-Jacobson KL. Cell Rep. 2017 Apr 18;19(3):461-470. PMID: 28423310
​
Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Peperzak V, Slinger E, Ter Burg J, Eldering E. Cell Death Differ. 2017 Jan;24(1):111-119. PMID: 27689871
​
MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. Vikström IB Slomp A, Carrington EM, Moesbergen LM, Chang C, Kelly GL, Glaser SP, Jansen JHM, Leusen JHW, Strasser A, Huang DCS, Lew AM, Peperzak V*, Tarlinton DM*. Cell Death Dis. 2016 Aug 25;7(8):e2345. PMID: 27560714
​​